Status:
COMPLETED
Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD
Lead Sponsor:
VA Greater Los Angeles Healthcare System
Collaborating Sponsors:
AstraZeneca
Conditions:
Pulmonary Disease, Chronic Obstructive
Asthma
Eligibility:
All Genders
40+ years
Phase:
PHASE4
Brief Summary
Use of beta-blockers has proven beneficial in patients with hypertension, heart failure, and in people who have suffered a heart attack. The use in patients who have Chronic Obstructive Pulmonary Dise...
Eligibility Criteria
Inclusion
- 40 years of age or older
- Mild to moderate COPD as defined by the American Thoracic Society
- Current treatment with a beta-blocker for either hypertension, myocardial infarction, or congestive heart failure.
Exclusion
- Recent (within 30 days) COPD exacerbation or requirement for oral steroid therapy within the last 6 months
- Any history of ventilator support requirement for COPD
- Patients with asthma or reactive airway disease (RAD) defined as obstructive lung disease with a \>15% improvement in FEV1 with beta-agonist therapy
- Relative or absolute contraindication to beta-blocker therapy
- Exposure to any investigational drugs within the previous 30 days
- Patients with any concurrent disease or condition, which in the judgment of the investigator would make the patient inappropriate for participation in the study were excluded from this study
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT03370835
Start Date
June 1 2004
End Date
June 1 2008
Last Update
December 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA West Los Angeles Medical Center
Los Angeles, California, United States, 90073